KUALA LUMPUR, May 22 (Bernama) -- Thermo Fisher Scientific, the world leader in serving science, has opened a new sterile drug facility in Singapore that will better enable customers to deliver new medicines and vaccines in the Asia Pacific (APAC) market.
In a statement, Thermo Fisher said the new facility also marked a significant milestone and investment in pandemic preparedness for Singapore, which is fast emerging as a biomedical hub in the APAC region.
Established with assistance from the Singapore Economic Development Board, in alignment with the government’s investment in preparedness for future health emergencies, the current Good Manufacturing Practices facility will provide rapid vaccine fill-finish capabilities along with the company’s end-to-end pharmaceutical development and manufacturing services.
The company’s executive vice president and chief operating officer, Michel Lagarde said the new site is an important extension of Thermo Fisher’s robust sterile fill-finish global network.
“With this expansion, we are strategically prepared, more than ever, to respond to our customers’ needs by supporting the accelerated delivery of critical vaccines and medicines to patients.”
The new facility includes a high-speed, fully automated aseptic fill-finish line for small and large molecules.
This strategic investment in Singapore complements new research capabilities at Thermo Fisher’s Customer Experience Center and Bioprocess Design Center, two other operational lab facilities that showcase the latest bioprocessing, life science and analytical technologies.
With over 250 products across diverse fields including molecular biology, genetic analysis and sequencing, chromatography and mass spectrometry, and cell therapy, the Customer Experience Center features an extensive product portfolio for Asia.
Additionally, the Bioprocess Design Center provides expertise in bioprocessing and process scale-up to support scientists and engineers with education and customised services to accelerate process development.
Together, these sites allow Thermo Fisher to better enable customers to accelerate their research, as well as develop and commercialise new medicines and vaccines in the APAC market.
-- BERNAMA
No comments:
Post a Comment